Trial Profile
Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Open-Label, Uncontrolled, Long-Term Study- Phase III Study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Sep 2023
Price :
$35
*
At a glance
- Drugs Paroxetine (Primary)
- Indications Social phobia
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 15 Oct 2008 Actual start date changed from Jul 2005 to Oct 2005 as reported by ClinicalTrials.gov
- 28 Jun 2007 Status change from in progress to completed.
- 16 Sep 2006 New trial record.